MPLT trades 25.4% below Wall Street's consensus target of $43.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MPLT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 30, 2026, MapLight Therapeutics, Inc. (MPLT) has a Wall Street consensus price target of $43.00, based on estimates from 4 covering analysts. With the stock currently trading at $34.30, this represents a potential upside of +25.4%. The company has a market capitalization of $1.55B.
Analyst price targets range from a low of $36.00 to a high of $48.00, representing a 28% spread in expectations. The median target of $45.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, MPLT trades at a trailing P/E of -9.4x. Analysts expect EPS to grow -16.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ACNBACNB Corporation | $612M | $59.93 | $61.00 | +1.8% | Buy | 11.1x | 2 |
PTGXProtagonist Therapeutics, Inc. | $7.8B | $121.63 | $117.25 | -3.6% | Buy | 30.2x | 26 |
TERNTerns Pharmaceuticals, Inc. | $4.8B | $52.95 | $55.50 | +4.8% | Buy | — | 16 |
ACLXArcellx, Inc. | $6.7B | $115.07 | $112.45 | -2.3% | Hold | — | 18 |
NRXPNRx Pharmaceuticals, Inc. | $69M | $4.00 | — | — | — | — | — |
SAVACassava Sciences, Inc. | $64M | $1.32 | — | — | Buy | — | 12 |
ACADACADIA Pharmaceuticals Inc. | $4.3B | $25.20 | $33.67 | +33.6% | Buy | 64.8x | 37 |
INVAInnoviva, Inc. | $1.7B | $23.14 | $37.00 | +59.9% | Buy | 6.5x | 10 |
PRAXPraxis Precision Medicines, Inc. | $10.1B | $350.06 | $584.00 | +66.8% | Buy | — | 16 |
NRXSNeurAxis, Inc. | $88M | $7.14 | — | — | — | — | — |
Quick answers to the most common questions about buying MPLT stock.
The consensus Wall Street price target for MPLT is $43, representing 25.4% upside from the current price of $34.3. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
MPLT has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $43 implies 25.4% upside from current levels.
MPLT's current price is $34.3 with a consensus target of $43 (25.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $48 for MPLT, while the most conservative target is $36. The consensus of $43 represents the median expectation. These targets typically reflect 12-month expectations.
MPLT is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MPLT stock forecast based on 4 Wall Street analysts shows a consensus price target of $43, with estimates ranging from $36 (bear case) to $48 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on MPLT, with a "Buy" consensus rating and $43 price target (25.4% upside). 4 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MPLT analyst price targets range from $36 to $48, a 28% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $43 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.